Psychedelics-assisted psychotherapy: Experiences with the limited medical use of LSD, MDMA, and psilocybin in Switzerland

Psychedelics-assisted psychotherapy (PAT) experienced intensive clinical and research activity in the 1950s through early 1970s, followed by international prohibition and a prolonged period in which work moved into non‑legal contexts. A renewed research ‘‘renaissance’’ began in the mid‑1990s and gathered pace thereafter, with Switzerland occupying an early leading role in some areas of basic and clinical research. Regulatory developments in Switzerland have allowed a tightly limited medical use of LSD, MDMA and, more recently, psilocybin under individual exemption permits issued by the Federal Office of Public Health (BAG). Aicher and colleagues set out to describe current treatment practice of PAT in Switzerland. The paper aims to give an overview of the regulatory context, how exemption permits are applied and used in practice, typical indications and treatment settings, the phases of PAT and psychotherapeutic embedding, and practical issues such as therapist competencies, ethical standards, quality assurance and documentation. The authors position this descriptive account as an insight into a nearly decade‑long, legally sanctioned but narrowly circumscribed implementation of PAT outside clinical trials in Switzerland, with potential relevance for international practice.

The extracted text does not present a formal methods section describing a systematic study design. Instead, the article is a descriptive account that draws on regulatory history, the authors' knowledge of Swiss practice and official BAG exemption procedures. Reported figures (for example the number of exemption permits and estimated treatments) appear to derive from BAG records and the authors' overview rather than from a prospectively collected dataset described in the text. Where procedural detail is provided it concerns the legal and practical structure of permits and typical clinical workflows rather than research methods: the paper explains the statutory basis for exemption permits (Article 8, paragraph 5 of the Swiss Narcotics Act), the scope of permits (individual patient and single substance), typical durations and possibilities for extension, and practice elements such as pre‑session preparation, the psychedelic session itself, and subsequent integration. No systematic sampling, data‑collection instruments, statistical analysis plan or formal qualitative methods are described in the extracted text.

Aicher and colleagues report that since 2014 the BAG has issued over 1000 individual exemption permits for the limited medical use of LSD, MDMA and, from 2021, psilocybin. These permits were granted to roughly 60 therapists and, over the same period, the authors estimate approximately 2000 to 3000 psychedelic treatment sessions have been performed in Switzerland. Earlier historical notes indicate that limited permits were also issued in 1988–1993, and that a broader international revival of research began in the mid‑1990s. The permits are single‑patient, single‑substance authorisations, valid for one year with the possibility of extension when clinically indicated. Decision‑making about dose, number and frequency of substance sessions, the therapeutic setting and the form and intensity of accompanying psychotherapy is left to the permit holder and tailored to the individual patient. Delegation of parts of the treatment to suitably experienced, including non‑medical, colleagues (for example psychotherapists) is possible, but the ultimate responsibility remains with the permit holder. In terms of indications, the extracted text states that exemption permits have primarily been issued for the better‑researched targets such as depression, post‑traumatic stress disorder (PTSD) and anxiety disorders, although permits are not formally restricted to specific diagnoses. Both outpatient and, in selected cases, inpatient care are used depending on severity and safety considerations. Most treatments to date have occurred in individual settings, but an increasing number employ group formats; the authors describe practical differences between these modalities. Clinical practice elements reported include extended, often mostly non‑talking psychedelic sessions with preparatory psychotherapy and an emphasis on integration work after the acute effects subside. Integration is framed as a longer‑term psychotherapeutic process aimed at making insights from the psychedelic experience useful in daily life; methods noted include psychotherapy, creative activities, meditation and nature contact. The description emphasises particular therapist competencies: sustained calm presence, tolerance for long silent phases, intuitive and experience‑based interventions, and readiness to manage rare acute psychological or somatic emergencies. Quality and ethics practices described include adherence to general medical and psychotherapeutic ethical principles, informed consent, and the recommendation of regular peer supervision, intervision groups and advanced training with professional societies. Therapists are requested to document acute effects and adverse events via patient self‑report questionnaires; however, the extracted text notes that documentation obligations are limited to routine medical practice and that there is no binding, systematic accompanying research. The authors warn that without more structured data collection many clinical insights may go unrecorded. The international context is briefly described: at the time of writing Switzerland was among very few countries permitting PAT outside clinical trials; examples of other jurisdictions where regulated or partially regulated clinical uses have appeared include recent regulatory changes in Australia and select permissions in Canada, while other countries show diverse patterns of clinical, indigenous, or recreational use.

The authors interpret Switzerland's exemption framework as providing a rare, nearly decade‑long opportunity to offer personalised PAT in a legally regulated, therapeutic setting. They suggest that this experience can generate practical lessons for implementing PAT elsewhere and could expand psychotherapy options for some psychiatric disorders. Emphasis is placed on the need for therapist training, ethical standards and quality assurance structures—such as supervision, peer exchange and professional networks—to support safe and competent practice. At the same time, the paper highlights important limitations and uncertainties. Chief among these is the absence of a mandated, systematic programme of accompanying research or registry data; documentation is currently limited to routine clinical recording and voluntary questionnaire use, increasing the risk that valuable clinical knowledge will not be captured. The authors also flag evolving demand and new practical and ethical challenges as PAT interest grows. They therefore call for greater sensitisation of PAT therapists to the importance of systematic questionnaire‑based documentation and for ongoing professional development to maintain treatment quality. In positioning their observations relative to prior work, the authors note that the Swiss history of earlier research and the more recent renaissance align with international trends, but stress that Switzerland’s regulatory route—individual exemption permits under the Narcotics Act—remains a comparatively unique model. They present their account as descriptive rather than evaluative and acknowledge the developing nature of the field and the need for better structured data to inform future practice and policy.

The authors conclude that the Swiss exemption article in the Narcotics Act has enabled almost ten years of limited, therapeutically individualised PAT, representing a nearly unique opportunity internationally to provide personalised psychedelic therapy outside clinical trials. They caution that, because documentation is limited to standard medical practice and there is no binding systematic follow‑up research, many insights may remain uncaptured. The paper ends with a call to sensitize PAT therapists to the importance of accompanying questionnaire research and improved documentation to preserve and learn from clinical experience.